NATCOPHARM vs VIYASH: Stock Comparison

Natco Pharma Limited vs Viyash Scientific Ltd

Live data: 28 July 2026, 4:08 PM IST • Source: NSE and company filings

Natco Pharma Limited is the larger company by market capitalisation. Natco Pharma Limited shows a lower P/E, a higher ROE and a higher dividend yield, while Viyash Scientific Ltd shows faster revenue growth and a higher ROCE. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Natco Pharma Limited and Viyash Scientific Ltd on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, NATCOPHARM is more favourable on 8 of 13 scored metrics and VIYASH on 5These counts are context-free and are not an overall rating.

Key Differences

Market Cap
NATCOPHARM is the larger company
₹16,536 Cr vs ₹11,038 Cr
P/E Ratio
NATCOPHARM has a lower P/E
11.68x vs 64x
P/B Ratio
NATCOPHARM has a lower P/B
1.8x vs 3.9x
EPS
NATCOPHARM has higher earnings per share
₹79.24 vs ₹4.06
Dividend Yield
NATCOPHARM has a higher dividend yield
0.52% vs 0%
Revenue Growth (TTM YoY)
VIYASH has faster revenue growth
0% vs -39.6%
EPS Growth (TTM YoY)
VIYASH has faster EPS growth
0% vs -34.1%
Qtr Sales Growth
VIYASH has stronger quarterly sales growth
129% vs -39.5%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricNATCOPHARMVIYASH
SectorHealthcare
IndustryPharmaceuticals

Price

MetricNATCOPHARMVIYASH
Live Price₹925.05₹253.45
Day Change-0.22%-2.41%
Volume1.52 L9.28 L
52-Week High₹1,226.8₹298
52-Week Low₹789₹178.13
Distance from 52W High-24.6%-14.95%

Valuation

MetricNATCOPHARMVIYASH
Market Cap₹16,536 Cr₹11,038 Cr
P/E Ratio11.68x64x
P/B Ratio1.8x3.9x
EPS₹79.24₹4.06
Book Value₹514.92₹66.6
Dividend Yield0.52%0%

Growth

MetricNATCOPHARMVIYASH
Revenue Growth (TTM YoY)-39.6%0%
EPS Growth (TTM YoY)-34.1%0%
Qtr Sales Growth-39.5%129%
Qtr Profit Growth-34.1%455%

Profitability & Leverage

MetricNATCOPHARMVIYASH
ROE16.9%11%
ROCE17.1%19%
Net Margin34.78%6.57%
Operating Margin35.2%19.1%
Debt to Equity0.08x0.17x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricNATCOPHARMVIYASH
Promoter Holding49.14%0%
FII Holding16.99% 0.38 pp4.5% 1.56 pp
DII Holding5.62% 0.16 pp3.75% 4.24 pp
Public Holding27.97% 0.22 pp30.34% 2.67 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Natco Pharma Limited and Viyash Scientific Ltd.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.